Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Hydralazine (compound)


PubChem
Name: Hydralazine
PubChem Compound ID: 3637
Description: A direct-acting vasodilator that is used as an antihypertensive agent.
Molecular formula: C8H8N4
Molecular weight: 160.176 g/mol
Synonyms:
C-5068; Hydrallazine; BA 5968; KBio1_000117; Hidralazina [Spanish]; 1(2H)-Phthalazinone hydrazone; HSDB 434; NSC126699; Hidralazina [INN-Spanish]; Hipoftalin.
show more »
DrugBank
Identification
Name: Hydralazine
Name (isomeric): DB01275
Drug Type: small molecule
Description: A direct-acting vasodilator that is used as an antihypertensive agent.
Synonyms:
Hydralazine hydrochloride
Brand: Apresoline
Brand name mixture: BiDil(isosorbide dinitrate + hydralazine hydrochloride)
Category: Vasodilator Agents, Antihypertensive Agents
CAS number: 86-54-4
Pharmacology
Indication: For the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.
Pharmacology:
A vasodilator, hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced ...
show more »
Mechanism of Action:
Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. It has also been suggested that cyclic 3',5'-adenosine monophosphate (cy...
show more »
Absorption: Hydralazine is rapidly and extensively absorbed (up to 90%) from the gastrointestinal tract and undergoes extensive first-pass metabolism by genetic polymorphic acetylation. Oral bioavailability of hydralazine is dependent upon acetylator phenotype. Bioavailability is approximately 31% in slow acetylators and 10% in fast acetylators.
Protein binding: 87%
Biotransformation: Hydralazine, when administered orally, undergoes extensive first-pass metabolism by genetic polymorphic acetylation, which is responsible for a threefold range of oral bioavailability. Intravenously administered hydralazine does not undergo first-pass metabolism and, therefore, is not affected by acetylator phenotype. After the drug reaches the systemic circulation, it is combined with endogenous aldehydes and ketones, including pyruvic acid, to form hydrazone metabolites. The active metabolites, hydralazine acetonide hydrazone and hydralazine pyruvate hydrazone, are equipotent with the parent, hydralazine.
Route of elimination: Hydralazine undergoes extensive hepatic metabolism; it is excreted mainly in the form of metabolites in the urine.
Half Life: 3 to 7 hours
Toxicity: Oral LD50 in rats: 173 and 187 mg/kg
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
MetoprololIncreased effect of both drugs
TreprostinilAdditive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
PropranololIncreased effect of both drugs

Targets


Enzymes